Avalyn Pharma Inc. Common Stock (AVLN) vs Nektar Therapeutics (NKTR)
A side-by-side comparison of Avalyn Pharma Inc. Common Stock and Nektar Therapeutics across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AVLN
Avalyn Pharma Inc. Common Stock
$25.94HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
NKTR
Nektar Therapeutics
$40.38HealthcareDelayed quote: Oct 6, 2026, 12:00 PM EDT
Total return — AVLN vs NKTR
growth of $100 · dividends reinvested · last 1yAVLN -8.3% (-8.3%/yr)NKTR -53.7% (-53.7%/yr)AVLN compounded faster over this window
AVLN NKTR
AVLN vs NKTR: by the numbers
- •NKTR is the larger company ($1.16B vs $1.15B market cap).
- •Both run net losses; AVLN's is the smaller (0.00% vs -287.84% net margin).
Metrics side by side
Valuation
| Metric | AVLN | NKTR |
|---|---|---|
| P/S ratio | N/A | 21.22 |
| P/B ratio | 2.89 | 1.28 |
Profitability
| Metric | AVLN | NKTR |
|---|---|---|
| Gross margin | 0.00% | 99.36% |
| Operating margin | 0.00% | -240.38% |
| Net margin | 0.00% | -287.84% |
| ROE | N/A | -17.40% |
| ROIC | -67.73% | -12.53% |
Growth (annualized)
| Metric | AVLN | NKTR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -12.34% |
| Total return CAGR (5Y) | N/A | -30.33% |
Go deeper
Dig into the metrics
Avalyn Pharma Inc. Common Stock ROENektar Therapeutics ROEAvalyn Pharma Inc. Common Stock operating marginNektar Therapeutics operating marginAvalyn Pharma Inc. Common Stock revenue growthNektar Therapeutics revenue growthAvalyn Pharma Inc. Common Stock free cash flowNektar Therapeutics free cash flow
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.